| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf32b60391b469c41e86c353437f5751 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886 |
| filingDate |
2019-10-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2fd87f63c8b09c6600c2496038af70da
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fc5234bf11666802bee26f9027370c58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7949d7ebf219bcffb6430ed4116630a0 |
| publicationDate |
2020-04-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2020079581-A1 |
| titleOfInvention |
Tumor mutation burden alone or in combination with immune markers as biomarkers for predicting response to targeted therapy |
| abstract |
The invention relates to the use of biomarkers for predicting the response to cancer (e.g. melanoma) treatments, for selecting a treatment for a cancer patient (e.g. using targeted therapy, e.g. using a BRAF and/or MEK inhibitor), for stratifying cancer patients into different treatment groups, for treating cancer patients, and for predicting clinical outcome in cancer. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2916259-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022144485-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022048106-A1 |
| priorityDate |
2018-10-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |